Fotvida (tivozanib) for kidney cancer – pro
Fotvida is FDA approved for this situation. Fotivda (tivozanib) is a prescription kinase inhibitor indicated for treating adults with relapsed or refractory advanced renal cell carcinoma (RCC) who have received two or more prior systemic therapies. It works as an antiangiogenic agent to reduce tumor blood supply and slow disease progression.
Fotvida Prescribing Information 2026
Jacob A, Shook J, Hutson TE: Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma. Future Oncol. 2020 Oct;16(28):2147-2164. doi: 10.2217/fon-2020-0443
NCCN Kidney Cancer 2026